Gephyrin Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gephyrin Neurons are neurons where gephyrin is highly expressed in inhibitory synapses. Gephyrin is the primary scaffold protein for GABA_A and glycine receptors, forming the postsynaptic scaffold at inhibitory synapses. [1]
The study of Gephyrin Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [3]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [4]
Gephyrin plays a crucial role in synaptic plasticity by dynamically regulating inhibitory receptor density at postsynaptic sites. Activity-dependent changes in gephyrin clustering contribute to homeostatic plasticity mechanisms that maintain excitatory-inhibitory balance in neural circuits. Dysregulation of these processes has been implicated in various neurological conditions. [5]
Targeting gephyrin-mediated inhibition represents a promising therapeutic strategy for neurodegenerative diseases. Small molecules that modulate gephyrin clustering or enhance GABA_A receptor function are under investigation for treating epilepsy and cognitive deficits in Alzheimer's disease. [6]
Additional evidence sources: [7]
Gephyrin is involved in GABAergic and glycinergic synapse formation. Dysregulation occurs in Alzheimer's Disease and ALS.
Fritschy JM, et al. (2020). Brain Research Bulletin. 2020. ↩︎
Jacob TC, et al. (2018). Journal of Neuroscience. 2018. ↩︎
Kirsch J, et al. (2021). Cellular and Molecular Life Sciences. 2021. ↩︎
Luscher B, et al. (2017). Neuropharmacology. 2017. ↩︎
Meier J, et al. (2019). Neurobiology of Learning and Memory. 2019. ↩︎
Tyagarajan SK, et al. (2020). Frontiers in Molecular Neuroscience. 2020. ↩︎
Wischhof L, et al. (2021). Molecular Psychiatry. 2021. ↩︎